Dexpramipexole An oral approach to eosinophilic asthma
Our subsidiary Areteia Therapeutics is now developing dexpramipexole for eosinophilic asthma.
Scroll to discover
Dexpramipexole
Dexpramipexole
Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.